Your Article Summary
Effectiveness and Safety of Colistin for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections
Infection, 06/09/09
Montero M et al. - Colistin is a safe option for the treatment of MDRP infections, with acceptable clinical outcomes. However, bacteriological eradication is difficult to achieve, especially in COPD patients.
Related Articles
Atomic Force Microscopy Investigation of the Morphology and Topography of Colistin-Heteroresistant Acinetobacter baumannii Strains as a Function of Growth Phase and in Response to Colistin Treatment
Antimicrobial Agents and Chemotherapy, 11/20/09
Relevance Score: 90%
Colistin in the 21st century
Current Opinion in Infectious Diseases, 11/02/09
Relevance Score: 88%
Post-neurosurgical multidrug-resistant Acinetobacter baumannii meningitis successfully treated with intrathecal colistin. A new case and a systematic review of the literature
International Journal of Infectious Diseases, 11/16/09
Relevance Score: 85%
Penetration of Colistin into Cerebrospinal Fluid
Antimicrobial Agents and Chemotherapy, 11/05/09
Relevance Score: 85%
Colistin and polymyxin B: A re-emergence
Indian Journal of Critical Care Medicine, 10/09/09
Relevance Score: 82%
Today in Antimicrobials...keeping you current
Receive free subspecialty "5-minute updates" via email
Screening of some Tanzanian medicinal plants for their trypanocidal and cytotoxic activities
Phytotherapy Research, 12/09/09
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial
The Lancet - Early Online Publication, 12/08/09
Linezolid in the Treatment of Multidrug-Resistant Tuberculosis
Clinical Infectious Diseases, 12/08/09
Today in Drug Resistance...keeping you current
Receive free subspecialty "5-minute updates" via email
Reduction of blood pressure in patients with treatment-resistant hypertension
Expert Opinion in Pharmacotherapy, 12/09/09
Linezolid in the Treatment of Multidrug-Resistant Tuberculosis
Clinical Infectious Diseases, 12/08/09
Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial
Archives of Drug Information, 12/08/09

See Latest Articles